| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Research Abstract |
In our recent studies, HBV clearance at an early stage by anti viral therapy restored hepatocytic TGF-beta signaling from fibro carcinogenesis toward the tumor suppression. Moreover, low pSmad3C and high pSmad3L positivity were significantly predictive of human HCC development. We conclude that pSmad3L and pSmad3C can serve as a useful markers determining whether you can defend development of viral related HCC by antiviral therapy. Using an individua s phospho-Smad3 markers, clinicians may be able to achieve more effective chemoprevention and individualized therapy for HBV infected patients.
|
